- In This Section
- Case Study #1:
58-year-old diagnosed with prostate carcinoma
ProstaScint Fusion Imaging fused with the patient's CT scan revealed abnormal activity in the region of the bilateral internal iliac nodes compatible with lymphadenopathy and no abnormal activity in the prostate bed. - Case Study #2:
76-year-old diagnosed with prostate cancer in 1992
ProstaScint scan with CT fusion from 2001 was prognostic and predated enlarged nodes on CT by four years. (PDF, 335k) - Case Study #3:
67-year-old with recent diagnosis of prostatic adenocarcinoma
ProstaScint imaging showed no evidence of high intensity signal outside of the prostate, suggesting that no metastasis had occurred. The lack of distant signal suggests that the disease is confined to the prostatic area and radiotherapy would be an appropriate option for therapy. (PDF, 350k)
This case presents one patient's experience with ProstaScint®. Individual results with ProstaScint may vary.
Case History
A 58-year-old Caucasian male was diagnosed with prostate carcinoma.
January of 2001: Initial PSA of 10.8 ng/mL. On biopsy, he was found to have a Gleason 6 prostate cancer that was later read as being a 4+4=8 adenocarcinoma. He was then treated on a clinical protocol involving neoadjuvant taxotere for 6 weeks.
May of 2001: He had a radical prostatectomy. After surgery, the patient's PSA remained undetectable until January of 2002 (8 months later).
February of 2002: He was treated with external beam radiation therapy, Zoladex and Eulexin.
July of 2002: He received Zoladex and Proscar as hormonal therapy and continued to have an undetectable PSA.
April 5, 2005: His PSA increased to 1.99 ng/mL.
March 22, 2005: A ProstaScint scan with CT fusion was done and showed disease limited to the iliac lymph node chain bilaterally.
Cytogen expresses appreciation for the contribution of this case study to:
D. Bruce Sodee, MD, Adriane Sodee and the Nuclear Medicine staff at
University Hospitals of Cleveland, Cleveland, Ohio
Case Report
ProstaScint/CT fusion of the pelvis and whole body ProstaScint imaging.
Clinical: Prostate cancer, status post prostatectomy and radiation therapy.
Technique: Following the IV administration of 5.9 mCi of indium 111 ProstaScint, spot images of the chest, abdomen and pelvis were obtained in the anterior and posterior projections after a 4-day delay. Tomographic images of the pelvis were obtained and reformatted into orthogonal planes. The pelvic tomographic images were additionally fused with the patient's CT scan of the pelvis.
Findings: There are no areas of abnormal tracer activity to suggest the presence of recurrent or residual disease within the prostate bed.
There is abnormal activity in the region of the bilateral internal iliac nodes compatible with lymphadenopathy.
Impression:
- Bilateral internal iliac malignant lymphadenopathy.
- No abnormal activity in the prostate bed.
